Agios Pharmaceuticals Inc (AGIO)
31.75
-0.06
(-0.19%)
USD |
NASDAQ |
Apr 24, 13:41
Agios Pharmaceuticals Cash from Operations (TTM): -296.06M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -296.06M |
September 30, 2023 | -289.74M |
June 30, 2023 | -299.44M |
March 31, 2023 | -306.93M |
December 31, 2022 | -309.48M |
September 30, 2022 | -327.41M |
June 30, 2022 | -341.24M |
March 31, 2022 | -384.31M |
December 31, 2021 | -407.32M |
September 30, 2021 | -372.62M |
June 30, 2021 | -355.65M |
March 31, 2021 | -306.15M |
December 31, 2020 | -290.76M |
September 30, 2020 | -334.97M |
June 30, 2020 | -352.36M |
March 31, 2020 | -372.71M |
December 31, 2019 | -370.62M |
September 30, 2019 | -351.20M |
June 30, 2019 | -329.45M |
March 31, 2019 | -308.69M |
December 31, 2018 | -304.42M |
September 30, 2018 | -304.69M |
June 30, 2018 | -318.56M |
Date | Value |
---|---|
March 31, 2018 | -310.16M |
December 31, 2017 | -285.23M |
September 30, 2017 | -262.00M |
June 30, 2017 | -233.32M |
March 31, 2017 | -16.50M |
December 31, 2016 | 38.56M |
September 30, 2016 | 59.26M |
June 30, 2016 | 83.47M |
March 31, 2016 | -70.37M |
December 31, 2015 | -76.95M |
September 30, 2015 | -54.20M |
June 30, 2015 | -52.85M |
March 31, 2015 | -57.90M |
December 31, 2014 | -59.35M |
September 30, 2014 | -65.20M |
June 30, 2014 | -56.71M |
March 31, 2014 | -71.46M |
December 31, 2013 | -56.40M |
September 30, 2013 | -54.41M |
June 30, 2013 | -50.83M |
March 31, 2013 | -45.56M |
December 31, 2012 | -49.55M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-407.32M
Minimum
Dec 2021
-289.74M
Maximum
Sep 2023
-336.76M
Average
-334.97M
Median
Sep 2020
Cash from Operations (TTM) Benchmarks
Alnylam Pharmaceuticals Inc | 104.16M |
Blueprint Medicines Corp | -436.85M |
Corcept Therapeutics Inc | 127.04M |
Ionis Pharmaceuticals Inc | -307.51M |
Madrigal Pharmaceuticals Inc | -324.23M |